Role of the AIVC
The Australian Influenza Vaccine Committee (AIVC) provides advice to the Therapeutic Goods Administration (TGA) on the composition of the seasonal influenza vaccine to be supplied each year in Australia.
The meeting is held annually following the September World Health Organisation (WHO) strain consultation meeting, which makes a decision on vaccine composition for the Southern Hemisphere. At the meeting the committee reviews and evaluates current available data related to the epidemiology, antigenic and genetic analysis of recent circulating regional and southern hemisphere influenza isolates and serological responses to the previous season vaccines.
AIVC is not involved in any decision making process under the Therapeutic Goods Act 1989.
Australian Influenza Vaccine Committee (AIVC) members
The current committee membership can be found on our AIVC members page.
Contacting AIVC
| aivc@health.gov.au | |
| Fax | +61 2 6203 1250 |
| Postal address | Australian Influenza Vaccine Committee Therapeutic Goods Administration PO Box 100 Woden ACT 2606 Australia Attn: Scheduling & Committee Support Section, MDP 122 |
Outcomes
- Meeting statementsAIVC Recommendations for the Composition of Influenza Vaccines for Australia in 2023The Australian Influenza Vaccine Committee (AIVC) recommendations for the composition of influenza vaccine for Australia in 2023
- Meeting statementsAIVC recommendations for Australia in 2022Australian Influenza Vaccine Committee (AIVC) recommendations
- Meeting statementsAIVC recommendations for Australia in 2021Australian Influenza Vaccine Committee (AIVC) recommendations